Business Context and Reporting Period
Nature's Sunshine Products, Inc. (NATR) is a natural health and wellness company manufacturing and selling nutritional and personal care products via a direct sales model of independent consultants. This Form 10-Q covers the quarterly period ended June 30, 2025. The company operates four geographic segments: Asia, Europe, North America, and Latin America and Other.
Key Financial Metrics
| Metric | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Net Sales | $114.8 million | $110.6 million | $228.0 million | $221.5 million |
| Gross Profit | $82.3 million | $78.9 million | $163.9 million | $157.9 million |
| Gross Margin | 71.7% | 71.4% | 71.9% | 71.3% |
| Operating Income | $4.3 million | $5.6 million | $10.4 million | $10.3 million |
| Net Income (Common Shareholders) | $5.3 million | $1.3 million | $10.1 million | $3.7 million |
| Diluted EPS | $0.28 | $0.07 | $0.54 | $0.19 |
| Cash and Equivalents | $81.3 million | (Balance Sheet Item) | ||
| Working Capital | $96.0 million | (Balance Sheet Item) | ||
| Debt | $0 (No outstanding balance) | (Revolving Credit Facility) |
Material Changes vs. Prior Period
- Revenue Growth: Q2 2025 net sales increased 3.8% year-over-year (2.2% excluding currency impacts). Growth was driven by Asia (+5.4%) and North America (+4.2%), while Latin America and Other declined slightly (-0.6%).
- Profitability Surge: Net income attributable to common shareholders jumped 294% in Q2 2025 compared to Q2 2024. This was primarily due to a significant swing in foreign exchange results, which turned a $1.5 million loss in Q2 2024 into a $3.0 million gain in Q2 2025.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased 13.2% in Q2 2025, attributed to timing of compensation costs, digital marketing investments, and non-recurring expenses.
- Share Repurchases: The company repurchased 1.0 million shares for $12.4 million in the first half of 2025, including a significant purchase of 833,000 shares from Fosun Pharma in June 2025.
Outlook, Risks, and Unusual Items
- China Joint Venture Buyback: On June 30, 2025, the company entered agreements to purchase Fosun Industrial's interest in two Chinese joint ventures for $7.0 million total ($3.9M and $3.1M). This follows Fosun Pharma dropping below 5% ownership, triggering a mandatory buyback clause.
- Trade Compliance Investigation: The company is undergoing an internal investigation regarding past compliance with U.S. trade controls, with voluntary disclosures made to the Bureau of Industry and Security (BIS) and OFAC. Management estimates potential violations represent less than 1% of net revenue and does not expect fines to be material, though outcomes are uncertain.
- Geopolitical Risks: Operations in Eastern Europe (Russia/Ukraine) continue at reduced levels due to ongoing conflict. The company monitors tariff impacts and inflationary pressures on raw materials and logistics.
- Tax Legislation: The "One Big Beautiful Bill Act" signed on July 4, 2025, modifies international tax frameworks. The company is currently evaluating the impact on future financial statements.
Investor Verification Checklist
- FX Sensitivity: Verify the sustainability of the $3.0 million foreign exchange gain in Q2 2025, as this was the primary driver of the net income surge.
- China JV Closing: Monitor the regulatory approval status of the $7.0 million buyback of the Chinese joint ventures from Fosun Industrial.
- Trade Compliance Outcome: Track the resolution of the voluntary disclosures to BIS and OFAC regarding trade control violations to assess potential fines or operational restrictions.
- SG&A Efficiency: Assess whether the 13.2% increase in SG&A expenses is a one-time timing issue or a structural increase in operating costs.
- Share Count: Note the reduction in outstanding shares to 17.6 million following the repurchase program and the Fosun transaction.